These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 34075567)

  • 21. PERMIT study: a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice.
    Villanueva V; D'Souza W; Goji H; Kim DW; Liguori C; McMurray R; Najm I; Santamarina E; Steinhoff BJ; Vlasov P; Wu T; Trinka E;
    J Neurol; 2022 Apr; 269(4):1957-1977. PubMed ID: 34427754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
    Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A
    Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study.
    Villanueva V; Montoya J; Castillo A; Mauri-Llerda JÁ; Giner P; López-González FJ; Piera A; Villanueva-Hernández P; Bertol V; Garcia-Escrivá A; Garcia-Peñas JJ; Garamendi I; Esteve-Belloch P; Baiges-Octavio JJ; Miró J; Falip M; Garcés M; Gómez A; Gil-López FJ; Carreño M; Rodriguez-Uranga JJ; Campos D; Bonet M; Querol R; Molins A; Tortosa D; Salas-Puig J
    Epilepsia; 2018 Sep; 59(9):1740-1752. PubMed ID: 30062784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics.
    Lin KL; Lin JJ; Chou ML; Hung PC; Hsieh MY; Chou IJ; Lim SN; Wu T; Wang HS
    Epilepsy Behav; 2018 Aug; 85():188-194. PubMed ID: 30032806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study.
    Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Kaneko S
    Acta Neurol Scand; 2018 Apr; 137(4):392-399. PubMed ID: 29250772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial.
    French JA; Krauss GL; Wechsler RT; Wang XF; DiVentura B; Brandt C; Trinka E; O'Brien TJ; Laurenza A; Patten A; Bibbiani F
    Neurology; 2015 Sep; 85(11):950-7. PubMed ID: 26296511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perampanel and lacosamide monotherapy in pediatric patients with newly diagnosed focal epilepsy: A prospective study evaluating efficacy, tolerability, and behavior.
    Zhou R; Qu R; Liu M; Huang DP; Zhou JY; Chen Y; Chen XQ
    Epilepsy Behav; 2023 Sep; 146():109353. PubMed ID: 37481960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychiatric and behavioral concerns of perampanel with concomitant levetiracetam in children with epilepsy.
    Kim JS; Kim WS; Sung WY; Woo H
    Epilepsy Behav; 2024 May; 154():109740. PubMed ID: 38547767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety.
    Lagae L; Villanueva V; Meador KJ; Bagul M; Laurenza A; Kumar D; Yang H
    Epilepsia; 2016 Jul; 57(7):1120-9. PubMed ID: 27221398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: A pooled post hoc analysis of four randomized, double-blind, phase III studies.
    Steinhoff BJ; Patten A; Williams B; Malhotra M
    Epilepsia; 2020 Feb; 61(2):278-286. PubMed ID: 31944276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures.
    Fogarasi A; Flamini R; Milh M; Phillips S; Yoshitomi S; Patten A; Takase T; Laurenza A; Ngo LY
    Epilepsia; 2020 Jan; 61(1):125-137. PubMed ID: 31912493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy and safety of perampanel as a first add-on therapy in patients with focal epilepsy: Three-year extension study.
    Im K; Lee SA; Kim JH; Kim DW; Lee SK; Seo DW; Lee JW
    Epilepsy Behav; 2021 Dec; 125():108407. PubMed ID: 34785411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A post-approval observational study to evaluate the safety and tolerability of perampanel as an add-on therapy in adolescent, adult, and elderly patients with epilepsy.
    Maguire M; Ben-Menachem E; Patten A; Malhotra M; Ngo LY
    Epilepsy Behav; 2022 Jan; 126():108483. PubMed ID: 34953337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial-onset epilepsy.
    Hsu WW; Sing CW; He Y; Worsley AJ; Wong IC; Chan EW
    CNS Drugs; 2013 Oct; 27(10):817-27. PubMed ID: 23918722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy and safety of adjunctive perampanel for the treatment of refractory focal-onset seizures in patients with epilepsy: A meta-analysis.
    Li Y; Zeng Y; Mu J; Zhou D
    Epilepsia Open; 2022 Jun; 7(2):271-279. PubMed ID: 34951748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-An Italian observational multicenter study.
    De Liso P; Vigevano F; Specchio N; De Palma L; Bonanni P; Osanni E; Coppola G; Parisi P; Grosso S; Verrotti A; Spalice A; Nicita F; Zamponi N; Siliquini S; Giordano L; Martelli P; Guerrini R; Rosati A; Ilvento L; Belcastro V; Striano P; Vari MS; Capovilla G; Beccaria F; Bruni O; Luchetti A; Gobbi G; Russo A; Pruna D; Tozzi AE; Cusmai R
    Epilepsy Res; 2016 Nov; 127():93-100. PubMed ID: 27568598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerability of adjuvant perampanel: an Australian multicenter real-world observational study in refractory focal and generalized epilepsy syndromes.
    Sagar P; Wawryk O; Vogrin S; Whitham E; Kiley M; Frasca J; Carne R; Seneviratne U; Cook MJ; Lawn N; Nikpour A; D'Souza WJ
    Epilepsy Behav; 2021 Jun; 119():107935. PubMed ID: 33930626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
    Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
    Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. WRAPPER study: Real-world effectiveness and tolerability of adjunctive perampanel for people with drug-resistant epilepsy in Hong Kong.
    Chan CCH; Leung HW
    Epilepsia Open; 2024 Feb; 9(1):345-354. PubMed ID: 38101856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST).
    Lattanzi S; Canafoglia L; Canevini MP; Casciato S; Irelli EC; Chiesa V; Dainese F; De Maria G; Didato G; Gennaro GD; Falcicchio G; Fanella M; Ferlazzo E; Gangitano M; La Neve A; Mecarelli O; Montalenti E; Morano A; Piazza F; Pizzanelli C; Pulitano P; Ranzato F; Rosati E; Tassi L; Di Bonaventura C;
    Seizure; 2022 Apr; 97():37-42. PubMed ID: 35320736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.